• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早发性精神分裂症谱系障碍(TEOSS)的治疗:人口统计学和临床特征

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics.

作者信息

Frazier Jean A, McCLELLAN Jon, Findling Robert L, Vitiello Benedetto, Anderson Robert, Zablotsky Benjamin, Williams Emily, McNAMARA Nora K, Jackson Joseph A, Ritz Louise, Hlastala Stefanie A, Pierson Leslie, Varley Jennifer A, Puglia Madeline, Maloney Ann E, Ambler Denisse, Hunt-Harrison Tyehimba, Hamer Robert M, Noyes Nancy, Lieberman Jeffrey A, Sikich Linmarie

机构信息

Drs. Frazier and Jackson, Mr. Zablotsky, and Ms. Noyes are with the Cambridge Health Alliance, Harvard Medical School, Cambridge, MA; Drs. McClellan and Hlastala, Ms. Pierson, and Ms. Varley are with the University of Washington, Seattle; Drs. Findling and McNamara are with the Case Western Reserve University, Cleveland; Dr. Vitiello and Ms. Ritz are with the National Institute of Mental Health, Bethesda, MD; Dr. Maloney is with the Maine Medical Center, Portland; Dr. Hunt-Harrison is with the John Umstead Hospital, Butner, NC; Dr. Lieberman is with Columbia University, New York; and Drs. Sikich, Hamer, and Ambler, Ms. Williams, Ms. Puglia, and Mr. Anderson are with the University of North Carolina at Chapel Hill..

Drs. Frazier and Jackson, Mr. Zablotsky, and Ms. Noyes are with the Cambridge Health Alliance, Harvard Medical School, Cambridge, MA; Drs. McClellan and Hlastala, Ms. Pierson, and Ms. Varley are with the University of Washington, Seattle; Drs. Findling and McNamara are with the Case Western Reserve University, Cleveland; Dr. Vitiello and Ms. Ritz are with the National Institute of Mental Health, Bethesda, MD; Dr. Maloney is with the Maine Medical Center, Portland; Dr. Hunt-Harrison is with the John Umstead Hospital, Butner, NC; Dr. Lieberman is with Columbia University, New York; and Drs. Sikich, Hamer, and Ambler, Ms. Williams, Ms. Puglia, and Mr. Anderson are with the University of North Carolina at Chapel Hill.

出版信息

J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):979-988. doi: 10.1097/chi.0b013e31807083fd.

DOI:10.1097/chi.0b013e31807083fd
PMID:17667477
Abstract

OBJECTIVE

We examined baseline demographic and clinical profiles of youths enrolled from 2001 to 2006 in the publicly funded multicenter, randomized controlled trial Treatment of Early-Onset Schizophrenia Spectrum Disorders.

METHOD

Youths (8-19 years) with schizophrenia (SZ) and schizoaffective disorder were recruited at four academic sites. Diagnosis was made via structured and clinical interviews. Assessments of psychiatric symptoms and social and global functioning were included.

RESULTS

A total of 119 youths were enrolled. The mean age at illness onset was 11.1 +/- 3.5 years. Patients with SZ and schizoaffective disorder had similar ratings on the Positive and Negative Symptom Scale, Brief Psychiatric Rating Scale for Children, and Clinical Global Impression-Severity Scale. The overall level of functioning was similar in the two groups. A comparison to published reports of adults with SZ indicates that these youths may have more severe symptoms based on results of the Positive and Negative Symptom Scale.

CONCLUSIONS

This is one of the largest samples of youths with SZ spectrum disorders studied to date and the largest assessment of youths with schizoaffective disorder. High rates of symptoms and general psychopathology were noted. There was a substantial degree of social and functional impairment. The symptom profiles are consistent with, but more severe than, those reported in the adult literature.

摘要

目的

我们研究了2001年至2006年参加公共资助的多中心随机对照试验“早发性精神分裂症谱系障碍治疗”的青少年的基线人口统计学和临床特征。

方法

在四个学术地点招募了患有精神分裂症(SZ)和分裂情感性障碍的青少年(8至19岁)。通过结构化访谈和临床访谈进行诊断。包括对精神症状以及社会和整体功能的评估。

结果

共招募了119名青少年。发病的平均年龄为11.1±3.5岁。精神分裂症患者和分裂情感性障碍患者在阳性和阴性症状量表、儿童简明精神病评定量表以及临床总体印象-严重程度量表上的评分相似。两组的整体功能水平相似。与已发表的成年精神分裂症患者报告相比,根据阳性和阴性症状量表的结果,这些青少年可能有更严重的症状。

结论

这是迄今为止研究的患有精神分裂症谱系障碍青少年的最大样本之一,也是对患有分裂情感性障碍青少年的最大评估。注意到症状和一般精神病理学的高发生率。存在相当程度的社会和功能损害。症状特征与成人文献中报道的一致,但更为严重。

相似文献

1
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics.早发性精神分裂症谱系障碍(TEOSS)的治疗:人口统计学和临床特征
J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):979-988. doi: 10.1097/chi.0b013e31807083fd.
2
Schizoaffective disorder: a form of schizophrenia or affective disorder?分裂情感性障碍:精神分裂症的一种形式还是情感障碍?
J Clin Psychiatry. 1999 Dec;60(12):874-82.
3
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.治疗早发性精神分裂谱系障碍研究中的神经认知结果。
J Am Acad Child Adolesc Psychiatry. 2012 May;51(5):496-505. doi: 10.1016/j.jaac.2012.02.001. Epub 2012 Mar 13.
4
Neurocognition in early-onset schizophrenia and schizoaffective disorders.早期发病精神分裂症和分裂情感性障碍的神经认知功能。
J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):52-60. doi: 10.1097/00004583-201001000-00009.
5
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.早期发病的精神分裂症谱系障碍(TEOSS)研究中的治疗反应和脱落的预测因素。
Psychiatry Res. 2017 Sep;255:248-255. doi: 10.1016/j.psychres.2017.05.038. Epub 2017 May 30.
6
Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders.发病年龄对精神分裂症谱系障碍临床特征的影响。
BMC Psychiatry. 2010 Aug 18;10:63. doi: 10.1186/1471-244X-10-63.
7
Comparison of older patients with bipolar disorder and schizophrenia/schizoaffective disorder.双相情感障碍老年患者与精神分裂症/分裂情感性障碍老年患者的比较。
Am J Geriatr Psychiatry. 2007 Jul;15(7):627-33. doi: 10.1097/JGP.0b013e318065b06b.
8
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.早发性精神分裂症谱系障碍(TEOSS)的治疗:基本原理、设计与方法
J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):969-978. doi: 10.1097/CHI.0b013e3180691779.
9
Premorbid adjustment in first episode schizophrenia and schizoaffective disorders: a comparison of social and academic domains.首发精神分裂症和分裂情感性障碍的病前适应:社会和学术领域的比较
Acta Psychiatr Scand. 2005 Jul;112(1):30-9. doi: 10.1111/j.1600-0447.2005.00555.x.
10
[Minor neurological and physical anomalies in patients with first-episode psychosis].[首发精神病患者的轻微神经和身体异常]
Encephale. 2013 Jun;39(3):149-54. doi: 10.1016/j.encep.2012.06.030. Epub 2012 Oct 12.

引用本文的文献

1
The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China.中国口服抗精神病药物治疗青少年精神分裂症的治疗特点
BMC Psychiatry. 2025 Jul 1;25(1):657. doi: 10.1186/s12888-025-07113-7.
2
Individual-specific functional connectome biomarkers predict schizophrenia positive symptoms during adolescent brain maturation.个体特异性功能连接组生物标志物可预测青少年大脑成熟过程中的精神分裂症阳性症状。
Hum Brain Mapp. 2020 Dec 2;42(5):1475-84. doi: 10.1002/hbm.25307.
3
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.
早期发病的精神分裂谱系障碍治疗中的临床反应时间研究。
J Child Adolesc Psychopharmacol. 2021 Feb;31(1):46-52. doi: 10.1089/cap.2020.0030. Epub 2020 Jul 1.
4
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.早发性精神分裂症谱系障碍治疗中抗精神病药物相关体重增加的预测因素和调节因素研究
J Child Adolesc Psychopharmacol. 2018 Sep;28(7):474-484. doi: 10.1089/cap.2017.0147. Epub 2018 Jun 19.
5
Dysregulated Maturation of the Functional Connectome in Antipsychotic-Naïve, First-Episode Patients With Adolescent-Onset Schizophrenia.抗精神病药初治、首发青少年起病精神分裂症患者功能连接组的失调成熟。
Schizophr Bull. 2019 Apr 25;45(3):689-697. doi: 10.1093/schbul/sby063.
6
Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.鲁拉西酮治疗青少年精神分裂症的疗效与安全性:一项为期6周的随机安慰剂对照研究。
J Child Adolesc Psychopharmacol. 2017 Aug;27(6):516-525. doi: 10.1089/cap.2016.0189. Epub 2017 May 5.
7
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.阿塞那平治疗青少年精神分裂症8周双盲试验及26周开放标签延长期的安全性和有效性
J Child Adolesc Psychopharmacol. 2015 Jun;25(5):384-96. doi: 10.1089/cap.2015.0027.
8
Antipsychotic-induced akathisia in delirium: A systematic review.谵妄中抗精神病药物所致静坐不能:一项系统评价。
Palliat Support Care. 2016 Feb;14(1):77-84. doi: 10.1017/S1478951515000784. Epub 2015 Jun 19.
9
Executive Dysfunction among Children with Antipsychotic Treated Schizophrenia.接受抗精神病药物治疗的精神分裂症儿童的执行功能障碍
Clin Psychopharmacol Neurosci. 2014 Dec;12(3):203-8. doi: 10.9758/cpn.2014.12.3.203. Epub 2014 Dec 26.
10
Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists.精神药物多药联用及超说明书用药的预测因素:一项针对儿童和青少年精神科医生的全国性调查。
J Psychiatr Pract. 2014 Nov;20(6):438-47. doi: 10.1097/01.pra.0000456592.20622.45.